Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.76
JNJ's Cash to Debt is ranked higher than
71% of the 1152 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. JNJ: 1.76 )
JNJ' s 10-Year Cash to Debt Range
Min: 0.5   Max: 6.01
Current: 1.76

0.5
6.01
Equity to Asset 0.53
JNJ's Equity to Asset is ranked higher than
64% of the 1034 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. JNJ: 0.53 )
JNJ' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.66
Current: 0.53

0.5
0.66
Interest Coverage 39.32
JNJ's Interest Coverage is ranked higher than
61% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 176.76 vs. JNJ: 39.32 )
JNJ' s 10-Year Interest Coverage Range
Min: 23.47   Max: 230.91
Current: 39.32

23.47
230.91
F-Score: 7
Z-Score: 5.20
M-Score: -2.65
WACC vs ROIC
8.82%
31.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 28.10
JNJ's Operating margin (%) is ranked higher than
96% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. JNJ: 28.10 )
JNJ' s 10-Year Operating margin (%) Range
Min: 18.63   Max: 28.2
Current: 28.1

18.63
28.2
Net-margin (%) 21.63
JNJ's Net-margin (%) is ranked higher than
95% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.10 vs. JNJ: 21.63 )
JNJ' s 10-Year Net-margin (%) Range
Min: 12.52   Max: 21.96
Current: 21.63

12.52
21.96
ROE (%) 25.46
JNJ's ROE (%) is ranked higher than
92% of the 1129 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.93 vs. JNJ: 25.46 )
JNJ' s 10-Year ROE (%) Range
Min: 17.02   Max: 30.17
Current: 25.46

17.02
30.17
ROA (%) 14.37
JNJ's ROA (%) is ranked higher than
91% of the 1161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.32 vs. JNJ: 14.37 )
JNJ' s 10-Year ROA (%) Range
Min: 8.93   Max: 17.94
Current: 14.37

8.93
17.94
ROC (Joel Greenblatt) (%) 108.74
JNJ's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1156 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.14 vs. JNJ: 108.74 )
JNJ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 52.08   Max: 110.98
Current: 108.74

52.08
110.98
Revenue Growth (3Y)(%) 3.50
JNJ's Revenue Growth (3Y)(%) is ranked higher than
67% of the 932 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. JNJ: 3.50 )
JNJ' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.4   Max: 14.8
Current: 3.5

1.4
14.8
EBITDA Growth (3Y)(%) 14.60
JNJ's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 839 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. JNJ: 14.60 )
JNJ' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -6.6   Max: 16.5
Current: 14.6

-6.6
16.5
EPS Growth (3Y)(%) 17.80
JNJ's EPS Growth (3Y)(%) is ranked higher than
84% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. JNJ: 17.80 )
JNJ' s 10-Year EPS Growth (3Y)(%) Range
Min: -8.6   Max: 20.2
Current: 17.8

-8.6
20.2
» JNJ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

JNJ Guru Trades in Q2 2014

Paul Tudor Jones 5,700 sh (+42.50%)
John Rogers 522,727 sh (+42.46%)
Richard Pzena 1,155,666 sh (+33.12%)
Sarah Ketterer 837,250 sh (+20.23%)
Jim Simons 3,145,500 sh (+18.29%)
Pioneer Investments 4,329,534 sh (+11.26%)
RS Investment Management 7,928 sh (+9.68%)
Ken Fisher 10,448,448 sh (+4.72%)
John Buckingham 46,512 sh (+1.78%)
Manning & Napier Advisors, Inc 4,769,286 sh (+0.89%)
James Barrow 17,065,230 sh (+0.66%)
Jean-Marie Eveillard 1,623,482 sh (+0.37%)
Ruane Cunniff 76,012 sh (+0.29%)
Dodge & Cox 38,625 sh (unchged)
Yacktman Fund 4,050,000 sh (unchged)
Michael Price 35,000 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Caxton Associates 100,000 sh (unchged)
Richard Perry 342,277 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Prem Watsa 84,700 sh (unchged)
Tom Gayner 574,200 sh (unchged)
Richard Snow 3,245 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Chuck Royce Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 12,242,420 sh (-0.48%)
Bill Frels 1,996,199 sh (-0.76%)
Tweedy Browne 4,196,224 sh (-1.71%)
Murray Stahl 31,683 sh (-2.00%)
Jeff Auxier 94,101 sh (-3.23%)
First Pacific Advisors 1,851,700 sh (-4.36%)
Steven Romick 1,750,000 sh (-4.63%)
Donald Yacktman 9,045,902 sh (-5.50%)
Mario Gabelli 373,186 sh (-5.54%)
Yacktman Focused Fund 3,300,000 sh (-13.16%)
Jeremy Grantham 14,297,233 sh (-18.65%)
Robert Olstein 87,000 sh (-20.91%)
John Hussman 1,325 sh (-50.00%)
George Soros 50,000 sh (-51.22%)
HOTCHKIS & WILEY 1,426,614 sh (-63.73%)
Ray Dalio 65,893 sh (-74.94%)
» More
Q3 2014

JNJ Guru Trades in Q3 2014

Joel Greenblatt 14,319 sh (New)
Paul Tudor Jones 17,426 sh (+205.72%)
Ray Dalio 84,193 sh (+27.77%)
Dodge & Cox 47,095 sh (+21.93%)
John Buckingham 47,934 sh (+3.06%)
John Rogers 536,616 sh (+2.66%)
Richard Pzena 1,184,416 sh (+2.49%)
Sarah Ketterer 853,150 sh (+1.90%)
Jean-Marie Eveillard 1,651,622 sh (+1.73%)
Richard Snow 3,270 sh (+0.77%)
Ruane Cunniff 76,259 sh (+0.32%)
Michael Price 35,000 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
John Hussman 1,325 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Pioneer Investments 4,202,682 sh (unchged)
Richard Perry 342,277 sh (unchged)
RS Investment Management 7,928 sh (unchged)
Tom Gayner 574,200 sh (unchged)
Warren Buffett 327,100 sh (unchged)
George Soros Sold Out
Ken Fisher 10,446,156 sh (-0.02%)
PRIMECAP Management 12,217,813 sh (-0.20%)
Jeff Auxier 93,726 sh (-0.40%)
Bill Frels 1,987,137 sh (-0.45%)
Tweedy Browne 4,163,934 sh (-0.77%)
Murray Stahl 31,318 sh (-1.15%)
Mario Gabelli 366,366 sh (-1.83%)
Prem Watsa 82,850 sh (-2.18%)
Yacktman Fund 3,900,000 sh (-3.70%)
Donald Yacktman 8,651,258 sh (-4.36%)
Robert Olstein 83,000 sh (-4.60%)
Yacktman Focused Fund 3,100,000 sh (-6.06%)
James Barrow 15,350,650 sh (-10.05%)
Jeremy Grantham 12,140,495 sh (-15.09%)
Jim Simons 2,643,000 sh (-15.98%)
First Pacific Advisors 1,473,500 sh (-20.42%)
Steven Romick 1,385,000 sh (-20.86%)
Manning & Napier Advisors, Inc 2,409,406 sh (-49.48%)
HOTCHKIS & WILEY 2,862 sh (-99.80%)
» More
Q4 2014

JNJ Guru Trades in Q4 2014

John Hussman 111,325 sh (+8301.89%)
Joel Greenblatt 790,529 sh (+5420.84%)
Paul Tudor Jones 92,664 sh (+431.76%)
John Rogers 632,132 sh (+17.80%)
Sarah Ketterer 930,583 sh (+9.08%)
RS Investment Management 8,308 sh (+4.79%)
John Buckingham 48,535 sh (+1.25%)
James Barrow 15,491,386 sh (+0.92%)
Murray Stahl 31,382 sh (+0.20%)
Prem Watsa 82,850 sh (unchged)
Tom Gayner 574,200 sh (unchged)
Richard Snow 3,270 sh (unchged)
Yacktman Fund 3,900,000 sh (unchged)
Michael Price 35,000 sh (unchged)
Brian Rogers 4,633,000 sh (unchged)
Yacktman Focused Fund 3,100,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Warren Buffett 327,100 sh (unchged)
First Pacific Advisors Sold Out
HOTCHKIS & WILEY Sold Out
Steven Romick Sold Out
Richard Pzena 1,183,966 sh (-0.04%)
Ken Fisher 10,424,607 sh (-0.21%)
Ruane Cunniff 75,946 sh (-0.41%)
Jeff Auxier 93,326 sh (-0.43%)
Donald Yacktman 8,611,359 sh (-0.46%)
Tweedy Browne 4,142,445 sh (-0.52%)
PRIMECAP Management 12,143,433 sh (-0.61%)
Manning & Napier Advisors, Inc 2,360,383 sh (-2.03%)
Jean-Marie Eveillard 1,616,927 sh (-2.10%)
Bill Frels 1,930,408 sh (-2.85%)
Jeremy Grantham 11,697,741 sh (-3.65%)
Dodge & Cox 44,235 sh (-6.07%)
Mario Gabelli 336,935 sh (-8.03%)
Richard Perry 312,610 sh (-8.67%)
Jim Simons 2,336,700 sh (-11.59%)
Robert Olstein 71,000 sh (-14.46%)
Ray Dalio 64,293 sh (-23.64%)
Pioneer Investments 2,722,369 sh (-35.22%)
» More
Q1 2015

JNJ Guru Trades in Q1 2015

Manning & Napier Advisors, Inc 2,802,122 sh (+18.71%)
Brian Rogers 4,633,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Yacktman Fund 3,900,000 sh (unchged)
Yacktman Focused Fund 3,000,000 sh (-3.23%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Johnson & Johnson

Bill Frels Comments on Johnson & Johnson - Oct 20, 2014

Due to the expansion of its pharmaceutical business, Johnson & Johnson (JNJ) contributed better-than- expected performance during the period. Sales soared by 21% due to almost a dozen recent drug launches and improving profitability, which may support a robust acquisition strategy that could reportedly beat management’s goal of 4.5% growth in annual drug sales through 2017.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

John Rogers' Ariel Fund Comments on Johnson & Johnson - Feb 28, 2014

Johnson & Johnson (JNJ) was a true favorite in the 1990s mega-cap bull market, with its glory days persisting until the end of 2002. From that point through 2010, it hit a relative rough patch. During the 1991 to 2002 period, Johnson & Johnson's revenues gained a remarkable +10.2% annually; in the subsequent period they slipped to a still-solid +6.8%. Its earnings decline was not as steep. The company compounded earnings per share (EPS) at a remarkable +13.6% in the 1990s and early 2000s period before slipping to +10.4% annually in the second era. Its price/earnings (P/E) ratios showcased its increasing popularity in the first period, as well as its fall from grace. Johnson & Johnson's earnings multiple soared from 26.1x in 1991 to a lofty 37.6x in 1998 before drifting down in the bear market to 24.9x at the end of 2002. From there it plummeted, however, to a low of just 12.9x at the end of 2010. Note that while investors chopped its P/E multiple in half from 2002 to 2010, its earnings per share more than doubled...

After its slide in the current century, Johnson & Johnson took the opportunity to reinvigorate itself. Alex Gorsky, who became CEO in 2012, led a major transformation; he charged his new operations head, Sandra Peterson, with structural improvements across the company. On the pharmaceutical side, it refocused its Research & Development (R&D) on blockbuster segments such as anti-coagulants and oncology. In its medical technology division, the company boldly exited the underperforming drug-eluding stent business and deployed foreign cash through the acquisition of high-margin specialty implant maker Synthes, a Swiss company. Johnson & Johnson even bolstered its consumer brands such as Neutrogena and Band-Aid, which offer lower margins but steady cash flows. More importantly, it has gotten past the embarrassing 2010 recalls of the children's versions of Tylenol, Motrin, Zyrtec and Benadryl, and all four are now back on the shelves. We always look forward, even when analyzing a 127-year old company, and at this point see a lean, mean heavyweight ready to compete.

From John Rogers (Trades, Portfolio)' Ariel International Fund & Ariel Global Fund fourth quarter 2013 commentary by Rupal J. Bhansali.

Check out latest stock trades

Top Ranked Articles about Johnson & Johnson

Google Set To Bring In A Difference In The World Of Surgery
The technology giant, Google (GOOG), has always striven to develop the best-in-kind products for the market and is often branded as the tech expert in the industry for its expertise in search optimization and its roaring popularity in the technology space. However, Google’s advent in the healthcare segment has been a sporadic one and does not find much of a mention by the analysts who follow the healthcare segment in the U.S. But currently the Google research team of biologists and chemists are in the top news section as Google is hoping to bring in advanced technology that could help surgeons to perform surgeries in a better way. Let’s get into the facts which have come into the limelight in the past few days with respect to Google’s strategic move to cater to the healthcare domain. Read more...
Guru Ken Fisher’s Top Five Quarterly Stocks
CEO and CIO of Fisher Investments, Ken Fisher, had a pretty busy third quarter. Fisher purchased a total of 47 new stocks. His third quarter portfolio holds 5454 stocks and is valued at over $46.911 billion. The following five stocks represent the five companies where Fisher holds the largest stake in. Read more...
Bill Frels Comments on Johnson & Johnson
Due to the expansion of its pharmaceutical business, Johnson & Johnson (JNJ) contributed better-than- expected performance during the period. Sales soared by 21% due to almost a dozen recent drug launches and improving profitability, which may support a robust acquisition strategy that could reportedly beat management’s goal of 4.5% growth in annual drug sales through 2017. Read more...
Top Five Mega-Cap Stocks That Gurus Like
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see mega cap companies which are held by the most gurus. The following five mega-capped companies are held by the largest number of gurus during the past quarter. Read more...
Money Managers Tweedy Browne Report Largest Stocks, Topped by Johnson & Johnson
Tweedy Browne (Trades, Portfolio) is a 93-year-old fund which focuses on undervalued securities, and which gained its investment approach from the late Benjamin Graham. The fund is owned and managed by William Browne, Thomas Shrager, John Spears and Robert Wyckoff, Jr. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 17.70
JNJ's P/E(ttm) is ranked higher than
91% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 64.60 vs. JNJ: 17.70 )
JNJ' s 10-Year P/E(ttm) Range
Min: 10.5   Max: 24.45
Current: 17.7

10.5
24.45
Forward P/E 16.23
JNJ's Forward P/E is ranked higher than
90% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. JNJ: 16.23 )
N/A
PE(NRI) 17.70
JNJ's PE(NRI) is ranked higher than
92% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 61.40 vs. JNJ: 17.70 )
JNJ' s 10-Year PE(NRI) Range
Min: 10.5   Max: 24.44
Current: 17.7

10.5
24.44
P/B 4.10
JNJ's P/B is ranked higher than
65% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. JNJ: 4.10 )
JNJ' s 10-Year P/B Range
Min: 2.68   Max: 6.21
Current: 4.1

2.68
6.21
P/S 3.90
JNJ's P/S is ranked higher than
61% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. JNJ: 3.90 )
JNJ' s 10-Year P/S Range
Min: 2.16   Max: 4.28
Current: 3.9

2.16
4.28
PFCF 19.60
JNJ's PFCF is ranked higher than
91% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. JNJ: 19.60 )
JNJ' s 10-Year PFCF Range
Min: 10.29   Max: 24.69
Current: 19.6

10.29
24.69
POCF 15.70
JNJ's POCF is ranked higher than
89% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.91 vs. JNJ: 15.70 )
JNJ' s 10-Year POCF Range
Min: 9   Max: 18.86
Current: 15.7

9
18.86
EV-to-EBIT 12.73
JNJ's EV-to-EBIT is ranked higher than
92% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.18 vs. JNJ: 12.73 )
JNJ' s 10-Year EV-to-EBIT Range
Min: 8.4   Max: 15.7
Current: 12.73

8.4
15.7
PEG 5.06
JNJ's PEG is ranked higher than
87% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. JNJ: 5.06 )
JNJ' s 10-Year PEG Range
Min: 1.24   Max: 246
Current: 5.06

1.24
246
Shiller P/E 21.70
JNJ's Shiller P/E is ranked higher than
94% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. JNJ: 21.70 )
JNJ' s 10-Year Shiller P/E Range
Min: 12.83   Max: 30.57
Current: 21.7

12.83
30.57
Current Ratio 2.36
JNJ's Current Ratio is ranked higher than
73% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. JNJ: 2.36 )
JNJ' s 10-Year Current Ratio Range
Min: 1.2   Max: 2.49
Current: 2.36

1.2
2.49
Quick Ratio 2.04
JNJ's Quick Ratio is ranked higher than
77% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. JNJ: 2.04 )
JNJ' s 10-Year Quick Ratio Range
Min: 0.94   Max: 2.18
Current: 2.04

0.94
2.18
Days Inventory 109.54
JNJ's Days Inventory is ranked higher than
73% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.81 vs. JNJ: 109.54 )
JNJ' s 10-Year Days Inventory Range
Min: 99.31   Max: 156.36
Current: 109.54

99.31
156.36
Days Sales Outstanding 54.48
JNJ's Days Sales Outstanding is ranked higher than
84% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 89.68 vs. JNJ: 54.48 )
JNJ' s 10-Year Days Sales Outstanding Range
Min: 50.65   Max: 61.4
Current: 54.48

50.65
61.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.80
JNJ's Dividend Yield is ranked higher than
85% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.30 vs. JNJ: 2.80 )
JNJ' s 10-Year Dividend Yield Range
Min: 1.64   Max: 3.84
Current: 2.8

1.64
3.84
Dividend Payout 0.48
JNJ's Dividend Payout is ranked higher than
96% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. JNJ: 0.48 )
JNJ' s 10-Year Dividend Payout Range
Min: 0.34   Max: 0.65
Current: 0.48

0.34
0.65
Dividend growth (3y) 7.00
JNJ's Dividend growth (3y) is ranked higher than
76% of the 481 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. JNJ: 7.00 )
JNJ' s 10-Year Dividend growth (3y) Range
Min: 7   Max: 17.1
Current: 7

7
17.1
Yield on cost (5-Year) 3.98
JNJ's Yield on cost (5-Year) is ranked higher than
86% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. JNJ: 3.98 )
JNJ' s 10-Year Yield on cost (5-Year) Range
Min: 2.33   Max: 5.46
Current: 3.98

2.33
5.46
Share Buyback Rate -1.10
JNJ's Share Buyback Rate is ranked higher than
76% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.60 vs. JNJ: -1.10 )
JNJ' s 10-Year Share Buyback Rate Range
Min: 2   Max: -4.9
Current: -1.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 13.60
JNJ's Price/Tangible Book is ranked lower than
51% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. JNJ: 13.60 )
JNJ' s 10-Year Price/Tangible Book Range
Min: 6.25   Max: 20.45
Current: 13.6

6.25
20.45
Price/DCF (Projected) 1.60
JNJ's Price/DCF (Projected) is ranked higher than
93% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. JNJ: 1.60 )
JNJ' s 10-Year Price/DCF (Projected) Range
Min: 0.97   Max: 3.6
Current: 1.6

0.97
3.6
Price/Median PS Value 1.20
JNJ's Price/Median PS Value is ranked higher than
80% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. JNJ: 1.20 )
JNJ' s 10-Year Price/Median PS Value Range
Min: 0.83   Max: 1.71
Current: 1.2

0.83
1.71
Price/Graham Number 3.20
JNJ's Price/Graham Number is ranked higher than
79% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.40 vs. JNJ: 3.20 )
JNJ' s 10-Year Price/Graham Number Range
Min: 1.98   Max: 5.3
Current: 3.2

1.98
5.3
Earnings Yield (Greenblatt) 7.90
JNJ's Earnings Yield (Greenblatt) is ranked higher than
90% of the 1148 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. JNJ: 7.90 )
JNJ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.4   Max: 11.9
Current: 7.9

6.4
11.9
Forward Rate of Return (Yacktman) 7.45
JNJ's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.03 vs. JNJ: 7.45 )
JNJ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1   Max: 17.9
Current: 7.45

1
17.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, PFE, RHHBY, NVS, ABT » details
Traded in other countries:JNJ.Germany, JNJB34.Brazil, JNJ.Mexico, JNJ.Argentina, JNJ.Chile, JNJ.Switzerland,
Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Company is engaged in the research and development, manufacture and sale of products in the health care field. It is a holding company, which has more than 275 operating companies conducting business in virtually all countries of the world. The Company's operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Consumer segment includes products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. The brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. The brands in the Women"s Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. Key products in the Pharmaceutical segment include: REMICADE a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; STELARA a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; INCIVO for the treatment of hepatitis C; INTELENCE and PREZISTA, treatments for HIV/AIDS; CONCERTA extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA extended-release tablets, for the treatment of schizophrenia and schizoaffective disorder; INVEGA SUSTENNA/XEPLION, for the treatment of schizophrenia in adults; RISPERDAL CONSTA, for the treatment of schizophrenia and for the maintenance treatment of Bipolar I Disorder; VELCADE, a treatment for multiple myeloma; ZYTIGA, a treatment for metastatic castration-resistant prostate cancer; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; PROCRIT, to stimulate red blood cell production; and XARELTO, an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may cause to pulmonary embolism (PE) in patients undergoing hip or knee repl
» More Articles for JNJ

Headlines

Articles On GuruFocus.com
North American Dividend Apr 26 2015 
1002072 Apr 17 2015 
What Were The Major Takeaways From Johnson & Johnson’s First Quarter Earnings? Apr 16 2015 
5 Best U.S. Dividend Growth Stocks Apr 15 2015 
Johnson & Johnson Beats Market Expectations Apr 15 2015 
Johnson & Johnson: Currency Headwinds Impacts Q1 Results Apr 14 2015 
Process Vs Outcome, Revisited Apr 07 2015 
Johnson and Johnson: Well Positioned for Long-Term Growth Apr 06 2015 
iRA Apr 06 2015 
Google And Johnson & Johnson Likely To Collaborate For Developing A Break Through Technology Mar 31 2015 


More From Other Websites
Apple and Exxon expected to join J&J, DuPont and others in upping dividends Apr 27 2015
Protests that forced companies to change Apr 27 2015
India Joint Replacement Market to Grow in Double Digits Through 2020 Apr 27 2015
Moody's: Outlook stable for pharmaceuticals; M&A activity to remain strong Apr 27 2015
Johnson & Johnson Reports 2015 First-Quarter Results: Apr 27 2015
4 Dividends and Buybacks That Should Not Be Ignored Apr 25 2015
J&J and DuPont Lead the Payout Parade Apr 24 2015
Abbott Laboratories (ABT) Earnings Analysis: By the Numbers Apr 24 2015
A Stronger Dollar Hurts the Performance of Large-Cap Stocks Apr 24 2015
The 4 Stocks That Dominated the DJIA on Friday Apr 24 2015
Eli Lilly (LLY) Earnings Analysis: By the Numbers Apr 24 2015
Johnson & Johnson’s Revenues Take a Hit with Stronger Dollar Apr 24 2015
Johnson & Johnson Posts Earnings, Lowers EPS Guidance on April 14 Apr 24 2015
The 10 global companies that get diversity: Study Apr 24 2015
JOHNSON & JOHNSON Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other... Apr 24 2015
Big Medical Device Makers Form Their First Industry Trade Group in Asia Apr 23 2015
Merck Gets a Boost of 69% in AQR Capital’s Portfolio Apr 23 2015
Strong dollar squeezes company earnings Apr 23 2015
Strong dollar squeezes company earnings Apr 23 2015
DepoMed Set To Grow On 'Transformative' Nucynta Deal Apr 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK